| name | endo-low-androgen-treatment-against |
| description | This skill advises against routinely treating women with low androgen levels due to hypopituitarism, adrenal insufficiency, surgical menopause, pharmacological glucocorticoid administration, or other associated conditions because of insufficient efficacy and long-term safety data. It is triggered when a clinician considers androgen therapy for a woman with known hypopituitarism, adrenal insufficiency, or history of bilateral oophorectomy. |
Recommend against routine treatment of low androgen levels in specific conditions
STEP 1 — Gather Information
Collect history of hypopituitarism, adrenal insufficiency, bilateral oophorectomy, or pharmacological glucocorticoid use; document symptoms attributed to low androgen (e.g., fatigue, low libido); obtain baseline androgen levels if measured to confirm low levels.
STEP 2 — Rule In / Rule Out
If the woman has hypopituitarism, adrenal insufficiency, bilateral oophorectomy, or glucocorticoid-induced adrenal suppression, rule in that routine androgen therapy is not recommended; otherwise, rule out this recommendation and consider other indications such as HSDD.
STEP 3 — Classify or Stratify
Classify the specific etiology (hypopituitarism, adrenal insufficiency, surgical menopause, glucocorticoid) to tailor discussion of potential risks and alternative management strategies.
STEP 4 — Decide
Decide to withhold routine testosterone or DHEA therapy and instead address symptoms through evaluation of other causes and non‑hormonal interventions.
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe androgen therapy based solely on low androgen levels in these conditions; avoid long‑term therapy without safety data; monitor for signs of androgen excess if a trial is considered; do not use androgen levels to diagnose a deficiency syndrome.
Concrete Clinical Example
A 48‑year‑old woman with prior bilateral oophorectomy reports decreased energy and libido; her clinician considers testosterone therapy; following this skill, routine androgen therapy is discouraged, and she is evaluated for thyroid dysfunction and mood disorders instead.
Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, American Society for Reproductive Medicine, American Congress of Obstetricians and Gynecologists, European Society of Endocrinology, International Menopause Society, 2014, https://doi.org/10.1210/jc.2014-2260
